|Myeloma UK news
First results from MUK six presented at ASH 2014
Initial data from MUK six, the second trial from the Myeloma UK Clinical Trial Network to have completed recruitment, were presented at the ASH 2014 Annual Meeting in San Francisco.
MUK six is a multi-centre Phase I/IIa trial evaluating panobinostat in combination with Velcade, thalidomide and dexamethasone (VTD-P) followed by panobinostat maintenance in relapsed and/or refractory myeloma patients.
Presented in poster format, Principal Investigator, Dr Rakesh Popat, University College Hospital, London reported that the recommended dose of panobinostat was established at 20mg and the combination of VTD-P was safe and well tolerated. In an intent-to-treat analysis, 15 out of 24 patients receiving the recommended dose of 20mg had achieved at least a partial response.
Chief Executive of Myeloma UK, Eric Low said, “We are delighted to have been given the opportunity to present the results of MUK six at ASH. As these are still early data, we look forward to learning more about the outcomes of the trial in due course.”
To view the abstract, click here
Myeloma UK Patient and Family Infodays
The dates and locations of the 2015 Patient and Family Myeloma Infodays are now available. We will be holding 11 Myeloma Infodays and one AL amyloidosis Infoday across the UK in 2015.
Details of all 2015 Infodays can be found on our website
The first Infoday of 2015 takes place on Saturday 28 February at the Nottingham Belfry Hotel, Nottingham, chaired by Dr Cathy Williams, Nottingham University Hospitals, Nottingham.
Please remind your patients, their families and carers to register for this and other upcoming Infodays. Further details of all Infodays can be found here
If you would like any posters or flyers for the Infodays, contact nicola.o’email@example.com
If you are interested in attending or taking part in an Infoday, contact firstname.lastname@example.org
Places for Infodays can be booked by:
Phone: (0)131 557 3332
For other Myeloma UK news, click here